These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2480212)

  • 1. [Selective elimination of human T-leukemia cells with the use of a conjugate of the A-chain of ricin and a monoclonal antibody against CD5-antigen of T-lymphocytes].
    Tonevitskiĭ AG; Toptygin AIu; Marks U; Filatov AV; Alekseev LP
    Dokl Akad Nauk SSSR; 1989; 307(6):1507-11. PubMed ID: 2480212
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of human leukemia cells in exponential or stationary growth phase to anti-CD5 immunotoxins. Role of intracellular processing events.
    Chignola R; Anselmi C; Franceschi A; Pasti M; Candiani C; Tridente G; Colombatti M
    J Immunol; 1994 Mar; 152(5):2333-43. PubMed ID: 7510743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
    Seon BK
    Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 6. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
    Rostaing-Capaillon O; Casellas P
    Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model.
    Manske JM; Buchsbaum DJ; Hanna DE; Vallera DA
    Cancer Res; 1988 Dec; 48(24 Pt 1):7107-14. PubMed ID: 2461252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen.
    Youle RJ; Uckun FM; Vallera DA; Colombatti M
    J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
    Manske JM; Buchsbaum DJ; Vallera DA
    J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation and study of cytotoxic properties of the immunotoxin anti-CD7/A-chain of ricin].
    Tonevitskiĭ AG; Ershova GV; Agapov II; Toptygin AIu; Korotkova OV; Shereshkov SN; Kadagidze ZG; Baryshnikov AIu
    Dokl Akad Nauk SSSR; 1991; 317(3):749-53. PubMed ID: 1720085
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic modulation by anti-CD5 immunotoxins.
    Manske JM; Buchsbaum DJ; Azemove SM; Hanna DE; Vallera DA
    J Immunol; 1986 Jun; 136(12):4721-8. PubMed ID: 3086441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
    Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
    J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and properties of CD5-ricin immunotoxin].
    Vikha GV; Uzhinova LD; Kashaeva AZh; Goshev VV; Krylov AV; Baryshnikov AIu; Vasilov RG
    Biull Eksp Biol Med; 1995 Jan; 119(1):76-9. PubMed ID: 7536484
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
    Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotoxin depletion of T cells and its effect on hematopoietic progenitor cells in human cord blood.
    Xu M; Lu S; Shen B; Li Y
    Chin Med J (Engl); 2001 Apr; 114(4):355-9. PubMed ID: 11780453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
    Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
    Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.